Author

Javier Gisbert

MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY
MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY

Javier Gisbert  et al.

DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY
DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY

Javier Gisbert  et al.

PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY
PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY

Javier Gisbert  et al.

IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH
IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH

Javier Gisbert  et al.

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE

Javier Gisbert  et al.

ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES
ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES

Javier Gisbert  et al.

HIV INFECTION IS ASSOCIATED WITH A LESS AGGRESSIVE PHENOTYPE OF INFLAMMATORY BOWEL DISEASE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY
HIV INFECTION IS ASSOCIATED WITH A LESS AGGRESSIVE PHENOTYPE OF INFLAMMATORY BOWEL DISEASE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY

Javier Gisbert  et al.

EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)
EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)

Javier Gisbert  et al.

ROOM FOR IMPROVEMENT IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION: LESSONS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROOM FOR IMPROVEMENT IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION: LESSONS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Javier Gisbert  et al.

COMPARISON OF THE EFFICACY OF A SECOND INTRAVENOUS OR SUBCUTANEOUS ANTI-TNF IN THE TREATMENT OF ULCERATIVE COLITIS. REAL-WORLD DATA FROM THE ENEIDA REGISTRY
COMPARISON OF THE EFFICACY OF A SECOND INTRAVENOUS OR SUBCUTANEOUS ANTI-TNF IN THE TREATMENT OF ULCERATIVE COLITIS. REAL-WORLD DATA FROM THE ENEIDA REGISTRY

Javier Gisbert  et al.

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 1,782 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 1,782 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES

Javier Gisbert  et al.

EFFECTIVENESS OF FIRST-LINE HELICOBACTER PYLORI ERADICATION TREATMENTS IN SPAIN: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF FIRST-LINE HELICOBACTER PYLORI ERADICATION TREATMENTS IN SPAIN: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

Javier Gisbert  et al.

BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

Javier Gisbert  et al.

THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB
THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB

Javier Gisbert  et al.

EFFECTIVENESS OF SECOND-LINE HELICOBACTER PYLORI ERADICATION TREATMENTS IN SPAIN: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF SECOND-LINE HELICOBACTER PYLORI ERADICATION TREATMENTS IN SPAIN: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

EFFECTIVENESS OF FIRST-LINE H. PYLORI ERADICATION THERAPY ACCORDING TO THE DAILY STATIN-USE: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF FIRST-LINE H. PYLORI ERADICATION THERAPY ACCORDING TO THE DAILY STATIN-USE: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

LOW ADHESION TO LATENT TUBERCULOSIS (TB) SCREENING RECOMMENDATIONS IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS: RESULTS OF THE INFEII REGISTRY OF GETECCU
LOW ADHESION TO LATENT TUBERCULOSIS (TB) SCREENING RECOMMENDATIONS IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS: RESULTS OF THE INFEII REGISTRY OF GETECCU

Javier Gisbert  et al.

Item 41 - 60 / 107
1 2
3
4 5 6